Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 7Phase 1 4Phase NA 3Phase EARLY_PHASE1 1Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 225Prostatic Neoplasms 113Neoplasms 104Multiple Myeloma 90Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 66Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 47Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Recurrence 40Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 33Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

sugemalimab 1pegaspargase 1Oxaliplatin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Extranodal NK-T-Cell × 1 year × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡